The DOI matches its Crossref record; 126 of the 126 references it cites were found in a registry or an index.
Pharmacological Treatment of Parkinson Disease: A Review
Abstract
IMPORTANCE: Parkinson disease is the second most common neurodegenerative disease worldwide. Although no available therapies alter the underlying neurodegenerative process, symptomatic therapies can improve patient quality of life. OBJECTIVE: To provide an evidence-based review of the initial pharmacological management of the classic motor symptoms of Parkinson disease; describe management of medication-related motor complications (such as motor fluctuations and dyskinesia), and other medication adverse effects (nausea, psychosis, and impulse control disorders and related behaviors); and discuss the management of selected nonmotor symptoms of Parkinson disease, including rapid eye movement sleep behavior disorder, cognitive impairment, depression, orthostatic hypotension, and sialorrhea. EVIDENCE REVIEW: References were identified using searches of PubMed between January 1985 and February 2014 for English-language human studies and the full database of the Cochrane Library. The classification of studies by quality (classes I-IV) was assessed using the levels of evidence guidelines from the American Academy of Neurology and the highest-quality data for each topic. RESULTS: Although levodopa is the most effective medication available for treating the motor symptoms of Parkinson disease, in certain instances (eg, mild symptoms, tremor as the only or most prominent symptom, aged <60 years) other medications (eg, monoamine oxidase type B inhibitors [MAOBIs], amantadine, anticholinergics, β-blockers, or dopamine agonists) may be initiated first to avoid levodopa-related motor complications. Motor fluctuations may be managed by modifying the levodopa dosing regimen or by adding several other medications, such as MAOBIs, catechol-O-methyltransferase inhibitors, or dopamine agonists. Impulse control disorders are typically managed by reducing or withdrawing dopaminergic medication, particularly dopamine agonists. Evidence-based management of some nonmotor symptoms is limited by a paucity of high-quality positive studies. CONCLUSIONS AND RELEVANCE: Strong evidence supports using levodopa and dopamine agonists for motor symptoms at all stages of Parkinson disease. Dopamine agonists and drugs that block dopamine metabolism are effective for motor fluctuations and clozapine is effective for hallucinations. Cholinesterase inhibitors may improve symptoms of dementia and antidepressants and pramipexole may improve depression. Evidence supporting other therapies for motor and nonmotor features is less well established.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Randomized Trial of Deep-Brain Stimulation for Parkinson's Disease
Deuschl, G., Schade-Brittinger, C., Krack, P., Volkmann, J., Schäfer, H., Bötzel, K., Daniels, C., Deutschländer, A., Dillmann, U., Eisner, W., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060281 · Cited by 2,944
The Sydney multicenter study of Parkinson's disease: The inevitability of dementia at 20 years
Hely, M. A., Reid, W. G. J., Adena, M. A., Halliday, G. M., & Morris, J. G. L. (2008) · Movement Disorders · doi:10.1002/mds.21956 · Cited by 2,246
Rascol, O., Brooks, D. J., Korczyn, A. D., De Deyn, P. P., Clarke, C. E., & Lang, A. E. (2000) · New England Journal of Medicine · doi:10.1056/nejm200005183422004 · Cited by 1,539
Self-citationImpulse Control Disorders in Parkinson Disease: A Cross-Sectional Study of 3090 Patients
Weintraub, D., Koester, J., Potenza, M. N., Siderowf, A. D., Stacy, M., Voon, V., Whetteckey, J., Wunderlich, G. R., & Lang, A. E. (2010) · Archives of Neurology · doi:10.1001/archneurol.2010.65 · Cited by 1,487
Self-citationAhlskog, J. E., & Muenter, M. D. (2001) · Movement Disorders · doi:10.1002/mds.1090 · Cited by 1,454
Barone, P., Antonini, A., Colosimo, C., Marconi, R., Morgante, L., Avarello, T. P., Bottacchi, E., Cannas, A., Ceravolo, G., Ceravolo, R., et al. (2009) · Movement Disorders · doi:10.1002/mds.22643 · Cited by 1,445
Neurostimulation for Parkinson's Disease with Early Motor Complications
Schuepbach, W. M. M., Rau, J., Knudsen, K., Volkmann, J., Krack, P., Timmermann, L., Hälbig, T. D., Hesekamp, H., Navarro, S. M., Meier, N., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1205158 · Cited by 1,430
Alzheimer's Disease and Parkinson's Disease
Nussbaum, R. L., & Ellis, C. E. (2003) · New England Journal of Medicine · doi:10.1056/nejm2003ra020003 · Cited by 1,351
Chronic Behavioral Disorders of Human REM Sleep: A New Category of Parasomnia
Schenck, C. H., Bundlie, S. R., Ettinger, M. G., & Mahowald, M. W. (1986) · Sleep · doi:10.1093/sleep/9.2.293 · Cited by 1,150
Seppi, K., Weintraub, D., Coelho, M., Perez‐Lloret, S., Fox, S. H., Katzenschlager, R., Hametner, E., Poewe, W., Rascol, O., Goetz, C. G., et al. (2011) · Movement Disorders · doi:10.1002/mds.23884 · Cited by 1,141
Cummings, J., Isaacson, S., Mills, R., Williams, H., Chi-Burris, K., Corbett, A., Dhall, R., & Ballard, C. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62106-6 · Cited by 954
A Double-Blind, Delayed-Start Trial of Rasagiline in Parkinson's Disease
Olanow, C. W., Rascol, O., Hauser, R., Feigin, P. D., Jankovic, J., Lang, A., Langston, W., Melamed, E., Poewe, W., Stocchi, F., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809335 · Cited by 901
Self-citationMeta‐analysis of early nonmotor features and risk factors for Parkinson disease
Noyce, A. J., Bestwick, J. P., Silveira‐Moriyama, L., Hawkes, C. H., Giovannoni, G., Lees, A. J., & Schrag, A. (2012) · Annals of Neurology · doi:10.1002/ana.23687 · Cited by 778
Association of dopamine agonist use with impulse control disorders in Parkinson disease
Weintraub, D., Siderowf, A. D., Potenza, M. N., Goveas, J., Morales, K. H., Duda, J. E., Moberg, P. J., & Stern, M. B. (2006) · Archives of Neurology · doi:10.1001/archneur.63.7.969 · Cited by 662
Rascol, O., Brooks, D., Melamed, E., Oertel, W., Poewe, W., Stocchi, F., & Tolosa, E. (2005) · The Lancet · doi:10.1016/s0140-6736(05)71083-7 · Cited by 641
Barone, P., Poewe, W., Albrecht, S., Debieuvre, C., Massey, D., Rascol, O., Tolosa, E., & Weintraub, D. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70106-x · Cited by 562
(2004) · Archives of Neurology · doi:10.1001/archneur.61.7.1044 · Cited by 561
de Rijk, M. C., Launer, L. J., Berger, K., Breteler, M. M. B., Dartigues, J. F., Baldereschi, M., Fratiglioni, L., Lobo, A., Martinez-Lage, J., Trenkwalder, C., et al. (2000) · PubMed · Cited by 528
Prevalence of Parkinson's disease in Europe : A collaborative study of population-based cohorts
de Rijk, M. C., Launer, L. J., Berger, K., Breteler, M. M. B., Dartigues, J. F., Baldereschi, M., Fratiglioni, L., Lobo, A., Martínez‐Lage, J. M., Trenkwalder, C., et al. (2000) · EUR Research Repository (Erasmus University Rotterdam) · Cited by 514
Pahwa, R., Factor, S. A., Lyons, K. E., Ondo, W. G., Gronseth, G., Bronte-Stewart, H., Hallett, M., Miyasaki, J., Stevens, J., & Weiner, W. J. (2006) · Neurology · doi:10.1212/01.wnl.0000215250.82576.87 · Cited by 499
Miyasaki, J. M., Shannon, K., Voon, V., Ravina, B., Kleiner-Fisman, G., Anderson, K., Shulman, L. M., Gronseth, G., & Weiner, W. J. (2006) · Neurology · doi:10.1212/01.wnl.0000215428.46057.3d · Cited by 487
Aurora (2010) · doi:10.5664/jcsm.27717 · Cited by 463
Randomized trial of deep brain stimulation for Parkinson disease: Thirty-six-month outcomes
Weaver, F. M., Follett, K. A., Stern, M., Luo, P., Harris, C. L., Hur, K., Marks, W. J., Rothlind, J., Sagher, O., Moy, C., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e31825dcdc1 · Cited by 452
Low, P. A. (1997) · JAMA · doi:10.1001/jama.1997.03540370036033 · Cited by 425
Rolinski, M., Fox, C., Maidment, I., & McShane, R. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006504.pub2 · Cited by 418
A controlled trial of antidepressants in patients with Parkinson disease and depression
Menza, M., Dobkin, R. D., Marin, H., Mark, M. H., Gara, M., Buyske, S., Bienfait, K., & Dicke, A. (2009) · Neurology · doi:10.1212/01.wnl.0000336340.89821.b3 · Cited by 414
Prevalence of smell loss in Parkinson's disease – A multicenter study
Haehner, A., Boesveldt, S., Berendse, H. W., Mackay-Sim, A., Fleischmann, J., Silburn, P. A., Johnston, A. N., Mellick, G. D., Herting, B., Reichmann, H., et al. (2009) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2008.12.005 · Cited by 403
Punding in Parkinson's disease: Its relation to the dopamine dysregulation syndrome
Evans, A., Katzenschlager, R., Paviour, D. C., Appel‐Cresswell, S., Lawrence, A., & Lees, A. J. (2004) · UCL Discovery (University College London) · Cited by 401
Poewe, W. H., Rascol, O., Quinn, N., Tolosa, E., Oertel, W. H., Martignoni, E., Rupp, M., & Boroojerdi, B. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70108-4 · Cited by 398
Neurogenic orthostatic hypotension: a double-blind, placebo-controlled study with midodrine
Jankovic, J., Gilden, J. L., Hiner, B. C., Kaufmann, H., Brown, D. C., Coghlan, C. H., Rubin, M., & Fouad-Tarazi, F. M. (1993) · The American Journal of Medicine · doi:10.1016/0002-9343(93)90230-m · Cited by 396
Incidence of parkinsonism and Parkinson disease in a general population: The Rotterdam Study
de Lau, L. M. L., Giesbergen, P. C. L. M., de Rijk, M. C., Hofman, A., Koudstaal, P. J., & Breteler, M. M. B. (2004) · Neurology · doi:10.1212/01.wnl.0000140706.52798.be · Cited by 360
Ferreira, J. J., Katzenschlager, R., Bloem, B. R., Bonuccelli, U., Burn, D., Deuschl, G., Dietrichs, E., Fabbrini, G., Friedman, A., Kanovsky, P., et al. (2013) · European Journal of Neurology · doi:10.1111/j.1468-1331.2012.03866.x · Cited by 348
A double-blind, dose-response study of midodrine in neurogenic orthostatic hypotension
Wright, R. A., Kaufmann, H. C., Perera, R., Opfer-Gehrking, T. L., McElligott, M. A., Sheng, K. N., & Low, P. A. (1998) · Neurology · doi:10.1212/wnl.51.1.120 · Cited by 331
Hallucinations in Parkinson disease
Diederich, N. J., Fénelon, G., Stebbins, G., & Goetz, C. G. (2009) · Nature Reviews Neurology · doi:10.1038/nrneurol.2009.62 · Cited by 312
Burn, D., Emre, M., McKeith, I., De Deyn, P. P., Aarsland, D., Hsu, C., & Lane, R. (2006) · Movement Disorders · doi:10.1002/mds.21077 · Cited by 310
Devos, D., Dujardin, K., Poirot, I., Moreau, C., Cottencin, O., Thomas, P., Destée, A., Bordet, R., & Defebvre, L. (2008) · Movement Disorders · doi:10.1002/mds.21966 · Cited by 274
Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD
Katzenschlager, R., Head, J., Schrag, A., Ben-Shlomo, Y., Evans, A., & Lees, A. J. (2008) · Neurology · doi:10.1212/01.wnl.0000310812.43352.66 · Cited by 271
Course in Parkinson disease subtypes: A 39-year clinicopathologic study
Rajput, A. H., Voll, A., Rajput, M. L., Robinson, C. A., & Rajput, A. (2009) · Neurology · doi:10.1212/wnl.0b013e3181ae7af1 · Cited by 270
KUNZ, D., & MAHLBERG, R. (2010) · Journal of Sleep Research · doi:10.1111/j.1365-2869.2010.00848.x · Cited by 269
Dopamine Dysregulation Syndrome: An Overview of its Epidemiology, Mechanisms and Management
OʼSullivan, S. S., Evans, A. H., & Lees, A. J. (2009) · CNS Drugs · doi:10.2165/00023210-200923020-00005 · Cited by 265
Anticholinergics for symptomatic management of Parkinson´s disease
Katzenschlager, R., Sampaio, C., Costa, J., & Lees, A. (2002) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003735 · Cited by 259
Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease
Weintraub, D., Mavandadi, S., Mamikonyan, E., Siderowf, A. D., Duda, J. E., Hurtig, H. I., Colcher, A., Horn, S. S., Nazem, S., Ten Have, T. R., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181ebdd79 · Cited by 255
Rektorová, I., Rektor, I., Bareš, M., Dostál, V., Ehler, E., Fanfrdlová, Z., Fiedler, J., Klajblová, H., Kulišt’ák, P., Ressner, P., et al. (2003) · European Journal of Neurology · doi:10.1046/j.1468-1331.2003.00612.x · Cited by 253
Hauser, R. A., Rascol, O., Korczyn, A. D., Jon Stoessl, A., Watts, R. L., Poewe, W., De Deyn, P. P., & Lang, A. E. (2007) · Movement Disorders · doi:10.1002/mds.21743 · Cited by 252
Self-citationOlanzapine and clozapine: Comparative effects on motor function in hallucinating PD patients
Goetz, C. G., Blasucci, L. M., Leurgans, S., & Pappert, E. J. (2000) · Neurology · doi:10.1212/wnl.55.6.789 · Cited by 249
Barone, P., Scarzella, L., Marconi, R., Antonini, A., Morgante, L., Bracco, F., Zappia, M., Musch, B., & and the Depression/Parkinson Italian Study Group (2006) · Journal of Neurology · doi:10.1007/s00415-006-0067-5 · Cited by 248
A double-blind placebo-controlled trial of botulinum toxin B for sialorrhea in Parkinson’s disease
Ondo, W. G., Hunter, C., & Moore, W. (2004) · Neurology · doi:10.1212/01.wnl.0000101713.81253.4c · Cited by 239
Mancini, F., Zangaglia, R., Cristina, S., Sommaruga, M. G., Martignoni, E., Nappi, G., & Pacchetti, C. (2003) · Movement Disorders · doi:10.1002/mds.10420 · Cited by 236
Long‐term follow‐up of impulse control disorders in Parkinson's disease
Mamikonyan, E., Siderowf, A. D., Duda, J. E., Potenza, M. N., Horn, S., Stern, M. B., & Weintraub, D. (2008) · Movement Disorders · doi:10.1002/mds.21770 · Cited by 235
Pathological gambling in Parkinson disease is reduced by amantadine
Thomas, A., Bonanni, L., Gambi, F., Di Iorio, A., & Onofrj, M. (2010) · Annals of Neurology · doi:10.1002/ana.22029 · Cited by 235
Impulsive and compulsive behaviors in Parkinson's disease
Evans, A. H., Strafella, A. P., Weintraub, D., & Stacy, M. (2009) · Movement Disorders · doi:10.1002/mds.22505 · Cited by 233
Contin, M., & Martinelli, P. (2010) · Journal of Neurology · doi:10.1007/s00415-010-5728-8 · Cited by 226
Hauser, R. A., Hsu, A., Kell, S., Espay, A. J., Sethi, K., Stacy, M., Ondo, W., O'Connell, M., & Gupta, S. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70025-5 · Cited by 210
Donepezil in Parkinson's disease dementia: A randomized, double‐blind efficacy and safety study
Dubois, B., Tolosa, E., Katzenschlager, R., Emre, M., Lees, A. J., Schumann, G., Pourcher, E., Gray, J., Thomas, G., Swartz, J., et al. (2012) · Movement Disorders · doi:10.1002/mds.25098 · Cited by 202
Evolution of mild cognitive impairment in Parkinson disease
Broeders, M., de Bie, R. M. A., Velseboer, D. C., Speelman, J. D., Muslimovic, D., & Schmand, B. (2013) · Neurology · doi:10.1212/wnl.0b013e31829c5c86 · Cited by 200
A randomized trial of botulinum toxin A for treatment of drooling
Lipp, A., Trottenberg, T., Schink, T., Kupsch, A., & Arnold, G. (2003) · Neurology · doi:10.1212/wnl.61.9.1279 · Cited by 199
Singer, W. (2003) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.74.9.1294 · Cited by 196
The effect of onset age on the clinical features of Parkinson’s disease
Wickremaratchi, M. M., Ben‐Shlomo, Y., & Morris, H. R. (2009) · European Journal of Neurology · doi:10.1111/j.1468-1331.2008.02514.x · Cited by 187
Long‐term antidyskinetic efficacy of amantadine in Parkinson's disease
Wolf, E., Seppi, K., Katzenschlager, R., Hochschorner, G., Ransmayr, G., Schwingenschuh, P., Ott, E., Kloiber, I., Haubenberger, D., Auff, E., et al. (2010) · Movement Disorders · doi:10.1002/mds.23034 · Cited by 185
Management of Parkinson's disease: An evidence-based review
Lang, A. E., & Lees, A. (2002) · Movement Disorders · doi:10.1002/mds.5554 · Cited by 184
Self-citationPathogenesis-Targeted, Disease-Modifying Therapies in Parkinson Disease
AlDakheel, A., Kalia, L. V., & Lang, A. E. (2013) · Neurotherapeutics · doi:10.1007/s13311-013-0218-1 · Cited by 180
Self-citationLagalla, G., Millevolte, M., Capecci, M., Provinciali, L., & Ceravolo, M. G. (2006) · Movement Disorders · doi:10.1002/mds.20793 · Cited by 179
Estimated life expectancy of Parkinson's patients compared with the UK population
Ishihara, L. S., Cheesbrough, A., Brayne, C., & Schrag, A. (2007) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2006.100107 · Cited by 173
Amantadine for Dyskinesias in Parkinson's Disease: A Randomized Controlled Trial
Sawada, H., Oeda, T., Kuno, S., Nomoto, M., Yamamoto, K., Yamamoto, M., Hisanaga, K., Kawamura, T., & for the Amantadine Study Group (2010) · PLoS ONE · doi:10.1371/journal.pone.0015298 · Cited by 168
Ives, N. J., Stowe, R. L., Marro, J., Counsell, C., Macleod, A., Clarke, C. E., Gray, R., & Wheatley, K. (2004) · BMJ · doi:10.1136/bmj.38184.606169.ae · Cited by 164
Sublingual Atropine for sialorrhea secondary to parkinsonism: A pilot study
Hyson, H. C., Johnson, A. M., & Jog, M. S. (2002) · Movement Disorders · doi:10.1002/mds.10276 · Cited by 163
Levels of evidence: Taking Neurology ® to the next level
Gross, R. A., & Johnston, K. C. (2009) · Neurology · doi:10.1212/01.wnl.0000342200.58823.6a · Cited by 162
Withdrawing amantadine in dyskinetic patients with Parkinson disease: The AMANDYSK trial
Ory‐Magne, F., Corvol, J., Azulay, J., Bonnet, A.-M., Brefel‐Courbon, C., Damier, P., Dellapina, E., Destée, A., Durif, F., Galitzky, M., et al. (2013) · Neurology · doi:10.1212/wnl.0000000000000050 · Cited by 158
Donepezil in the treatment of hallucinations and delusions in Parkinson’s disease
Fabbrini, G., Barbanti, P., Aurilia, C., Pauletti, C., Lenzi, G. L., & Meco, G. (2002) · Neurological Sciences · doi:10.1007/s100720200022 · Cited by 154
Waters, C., Sethi, K. D., Hauser, R. A., Molho, E., & Bertoni, J. M. (2004) · Movement Disorders · doi:10.1002/mds.20036 · Cited by 153
Amantadine in Parkinson's disease
Crosby, N. J., Deane, K. H., & Clarke, C. E. (2003) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003468 · Cited by 151
Lost in a jungle of evidence: We need a compass
Pincus, M. M. (2009) · Neurology · doi:10.1212/wnl.0b013e3181b26e15 · Cited by 149
Amantadine for dyskinesia in Parkinson's disease
Crosby, N. J., Deane, K. H., & Clarke, C. E. (2003) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003467 · Cited by 146
van Gerpen, J. A., Kumar, N., Bower, J. H., Weigand, S. D., & Ahlskog, J. E. (2006) · Archives of Neurology · doi:10.1001/archneur.63.2.205 · Cited by 146
Marsh, L., Biglan, K., Gerstenhaber, M., & Williams, J. R. (2008) · Movement Disorders · doi:10.1002/mds.22307 · Cited by 144
Schoffer, K. L., Henderson, R. D., O’Maley, K. A., & O’Sullivan, J. D. (2007) · Movement Disorders · doi:10.1002/mds.21428 · Cited by 144
Glycopyrrolate for sialorrhea in Parkinson disease
Arbouw, M. E. L., Movig, K. L. L., Koopmann, M., Poels, P. J. E., Guchelaar, H., Egberts, T. C. G., Neef, C., & van Vugt, J. P. P. (2010) · Neurology · doi:10.1212/wnl.0b013e3181d8c1b7 · Cited by 143
Perry, E. K., McKeith, I. G., THOMPSON, P., MARSHALL, E., Kerwin, J. M., Jabeen, S., Edwardson, J. A., Ince, P. G., Blessed, G., Irving, D., et al. (1991) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1991.tb00217.x · Cited by 138
Guidubaldi, A., Fasano, A. A., Ialongo, T., et al. (2011) · Movement Disorders · doi:10.1002/mds.23473 · Cited by 135
Genetics of Parkinson's disease: the yield
Spatola, M., & Wider, C. W. (2013) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(13)70011-7 · Cited by 133
Troeung, L., Egan, S. J., & Gasson, N. (2013) · PLoS ONE · doi:10.1371/journal.pone.0079510 · Cited by 132
Rivastigmine as alternative treatment for refractory REM behavior disorder in Parkinson's disease
Giacopo, R. D., Fasano, A. A., Quaranta, D., Marca, G. D., Bove, F., & Bentivoglio, A. R. (2012) · Movement Disorders · doi:10.1002/mds.24909 · Cited by 128
Hanagasi, H. A., Gurvit, H. I., Unsalan, P., Horozoğlu, H., Tuncer, N., Feyzioğlu, A., Günal, D. İ., Yener, G., Çakmur, R., Sahin, H. A., et al. (2011) · Movement Disorders · doi:10.1002/mds.23738 · Cited by 124
Invited Article: Lost in a jungle of evidence
French, J. A., & Gronseth, G. (2008) · Neurology · doi:10.1212/01.wnl.0000336533.19610.1b · Cited by 121
The clinical features of Parkinson's disease in 100 histologically proven cases.
Aj, H., Daniel, S. E., & Lees, A. J. (1993) · PubMed · Cited by 121
Korczyn, A. D. (2009) · Neurology · doi:10.1212/wnl.0b013e3181b26b8b · Cited by 120
Shibao, C. A., Okamoto, L. E., Gamboa, A. C., Yu, C., Diedrich, A., Raj, S. R., Robertson, D., & Biaggioni, I. (2010) · Hypertension · doi:10.1161/hypertensionaha.110.154898 · Cited by 111
Chinnapongse, R. B., Gullo, K. L., Nemeth, P. R., Zhang, Y., & Griggs, L. (2011) · Movement Disorders · doi:10.1002/mds.23929 · Cited by 107
Benztropine versus clozapine for the treatment of tremor in Parkinson's disease
Friedman, J. H., Koller, W. C., Lannon, M. C., Busenbark, K. L., Swanson‐Hyland, E., & Smith, D. (1997) · Neurology · doi:10.1212/wnl.48.4.1077 · Cited by 105
Long-lasting benefits of botulinum toxin type B in Parkinson’s disease-related drooling
Lagalla, G., Millevolte, M., Capecci, M., Provinciali, L., & Ceravolo, M. G. (2009) · Journal of Neurology · doi:10.1007/s00415-009-0085-1 · Cited by 100
Clinical features of dopamine agonist withdrawal syndrome in a movement disorders clinic
Pondal, M., Marras, C., Miyasaki, J., Moro, E., Armstrong, M. J., Strafella, A. P., Shah, B. B., Fox, S., Prashanth, L. K., Phielipp, N., et al. (2013) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2012-302684 · Cited by 99
Self-citationInvited Article: Practice parameters and technology assessments
Gronseth, G., & French, J. A. (2008) · Neurology · doi:10.1212/01.wnl.0000336535.27773.c0 · Cited by 93
Liu, J., Dong, J., Wang, L., Su, Y., Yan, P., & Sun, S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0076651 · Cited by 91
Weiss, H. D., & Marsh, L. (2012) · Neurology Clinical Practice · doi:10.1212/cpj.0b013e318278be9b · Cited by 84
Antidepressants for depression in Parkinson’s disease: systematic review and meta-analysis
Rocha, F. L., Murad, M. G., Stumpf, B. P., Hara, C., & Fuzikawa, C. (2013) · Journal of Psychopharmacology · doi:10.1177/0269881113478282 · Cited by 82
PREPARED: Comparison of prolonged and immediate release ropinirole in advanced Parkinson's disease
Stocchi, F., Giorgi, L., Hunter, B. N., & Schapira, A. H. V. (2011) · Movement Disorders · doi:10.1002/mds.23498 · Cited by 79
Ipratropium bromide spray as treatment for sialorrhea in Parkinson's disease
Thomsen, T. R., Galpern, W. R., Asante, A., Arenovich, T., & Fox, S. H. (2007) · Movement Disorders · doi:10.1002/mds.21730 · Cited by 78
Quetiapine in the treatment of psychosis in Parkinson’s disease
Shotbolt, P., Samuel, M., & David, A. S. (2010) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285610389656 · Cited by 75
Levodopa therapy in Parkinson's disease.
Koller, W. C., & Hubble, J. P. (1990) · PubMed · Cited by 74
Zonisamide in managing impulse control disorders in Parkinson’s disease
Bermejo, P. E., Ruíz-Huete, C., & Anciones, B. (2010) · Journal of Neurology · doi:10.1007/s00415-010-5603-7 · Cited by 72
Use of Ziprasidone in Parkinsonian Patients With Psychosis
Gómez‐Esteban, J. C., Zarranz, J. J., Velasco, F., Lezcano, E., Lachen, M. C., Rouco, I., Bárcena, J., Boyero, S., Ciordia, R., & Allue, I. (2005) · Clinical Neuropharmacology · doi:10.1097/01.wnf.0000164297.91643.ff · Cited by 68
Reichmann, H., Boas, J., MacMahon, D. G., Myllylä, V. V., Hakala, A., Reinikainen, K. J., & on behalf of the ComQol Study Group (2004) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.2004.00363.x · Cited by 67
Management of punding in Parkinson’s disease: an open-label prospective study
Fasano, A. A., Ricciardi, L., Pettorruso, M., & Bentivoglio, A. R. (2010) · Journal of Neurology · doi:10.1007/s00415-010-5817-8 · Cited by 60
The Entacapone to Tolcapone Switch Study Investigators (2006) · Movement Disorders · doi:10.1002/mds.21131 · Cited by 59
Adjuvant Therapy of Parkinsonian Tremor
Koller, W. C., & Herbster, G. (1987) · Archives of Neurology · doi:10.1001/archneur.1987.00520210023013 · Cited by 57
Domperidone and Parkinson’s Disease
Parkes, J. D. (1989) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-73899-9_20 · Cited by 57
Levodopa–carbidopa intestinal gel for treatment of advanced Parkinson’s disease
Fernandez, H. H., & Odin, P. (2011) · Current Medical Research and Opinion · doi:10.1185/03007995.2011.560146 · Cited by 57
An update expert opinion on management and research strategies in Parkinson's disease psychosis
Goldman, J. G., Vaughan, C. L., & Goetz, C. G. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.587122 · Cited by 56
Ziprasidone Versus Clozapine in the Treatment of Psychotic Symptoms in Parkinson Disease
Pintor, L., Valldeoriola, F., Baillés, E., et al. (2012) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e31824d5115 · Cited by 47
Ondo, W. G., Sethi, K. D., & Kricorian, G. (2007) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e3180616570 · Cited by 46
Management of hallucinations and psychosis in Parkinson's disease
Eng, M. L., & Welty, T. E. (2010) · The American Journal of Geriatric Pharmacotherapy · doi:10.1016/j.amjopharm.2010.08.004 · Cited by 46
Early Parkinson??s Disease: What is the Best Approach to Treatment
Hristova, A. H., & Koller, W. C. (2000) · Drugs & Aging · doi:10.2165/00002512-200017030-00002 · Cited by 44
Mizuno, Y., Kanazawa, I., Kuno, S., Yanagisawa, N., Yamamoto, M., Kondo, T., & Japanese Parkinson–Entacapone Study Group (2006) · Movement Disorders · doi:10.1002/mds.21218 · Cited by 44
Diagnosis and treatment of impulse control disorders in patients with movement disorders
Mestre, T., Strafella, A. P., Thomsen, T. R., Voon, V., & Miyasaki, J. M. (2013) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285613476127 · Cited by 44
Topiramate in managing impulse control disorders in Parkinson's disease
Bermejo, P. E. (2008) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2007.11.008 · Cited by 43
Hicks, C. W., Pandya, M., Itin, I., & Fernandez, H. H. (2011) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2011.03.003 · Cited by 43
Switch-Over from Tolcapone to Entacapone in Severe Parkinson’s Disease Patients
ONOFRJ, M. C., Thomas, A., Iacono, D., Iorio, A. D., & Bonanni, L. (2001) · European Neurology · doi:10.1159/000050749 · Cited by 42
Peripheral beta‐adrenergic blockade treatment of parkinsonian tremor
Foster, N. L., Newman, R. P., LeWitt, P. A., Gillespie, M., Larsen, T., & Chase, T. N. (1984) · Annals of Neurology · doi:10.1002/ana.410160412 · Cited by 41
Perez‐Lloret, S., Ñano, G., Carrosella, A., Gamzu, E. R., & Merello, M. (2011) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2011.05.021 · Cited by 40
Valproate as a treatment for dopamine dysregulation syndrome (DDS) in Parkinson’s disease
Sriram, A., Ward, H. E., Hassan, A., Iyer, S. S., Foote, K. D., Rodriguez, R. L., McFarland, N. R., & Okun, M. S. (2012) · Journal of Neurology · doi:10.1007/s00415-012-6669-1 · Cited by 40
Impulsive and compulsive behaviors in Parkinson's disease: A one-year follow-up study
Ávila, A., Cardona, X., Martín‐Baranera, M., Bello, J., & Sastre, F. F. (2011) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2011.05.044 · Cited by 40
Effects of indomethacin on postural hypotension in Parkinsonism.
Abate, G., Polimeni, R. M., Cuccurullo, F., Puddu, P., & Lenzi, S. (1979) · BMJ · doi:10.1136/bmj.2.6203.1466 · Cited by 38
Tarsy, D. (2012) · JAMA · doi:10.1001/jama.2012.4829 · Cited by 38
Sénard, J., Rascol, O., Rascol, A., et al. (1993) · Fundamental and Clinical Pharmacology · doi:10.1111/j.1472-8206.1993.tb00001.x · Cited by 20
Off spells and dyskinesias: Pharmacologic management of motor complications
Fernandez, H., Gálvez-Jiménez, N., & Khan, T. (2012) · Cleveland Clinic journal of medicine · doi:10.3949/ccjm.79.s2a.02 · Cited by 19
Apomorphine in the treatment of Parkinson disease and other movement disorders
Gunzler, S. A. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560902828344 · Cited by 16
Cited by
Kalia, L. V., & Lang, A. E. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61393-3 · Cited by 6,184
Self-citationPoewe, W., Seppi, K., Tanner, C. M., Halliday, G. M., Brundin, P., Volkmann, J., Schrag, A.-E., & Lang, A. E. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.13 · Cited by 5,415
Self-citationBloem, B. R., Okun, M. S., & Klein, C. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00218-x · Cited by 3,920
Ferroptosis and its potential role in the physiopathology of Parkinson’s Disease
Mahoney-Sánchez, L., Bouchaoui, H., Ayton, S., Devos, D., Duce, J. A., & Devedjian, J.-C. (2021) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2020.101890 · Cited by 553
Tapeinos, C., Battaglini, M., & Ciofani, G. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.08.033 · Cited by 539
Metadata
- Authors
- Connolly, B. S., & Lang, A. E.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2014-04-23
- Volume
- 311
- Issue
- 16
- Pages
- 1670
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2106350754
- Cited by
- 1,498
- References
- 126
- FWCI
- 68.29
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.